• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Business Officer Dwyer Donald

    5/14/25 8:38:41 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VANI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Dwyer Donald

    (Last) (First) (Middle)
    C/O VIVANI MEDICAL, INC.
    1350 S. LOOP ROAD

    (Street)
    ALAMEDA CA 94502

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vivani Medical, Inc. [ VANI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Business Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Common Stock Option $1.03 05/12/2025 A 70,000 (1) 05/11/2035(1) Common Stock 70,000 $0 70,000 D
    RSUs (2) 05/12/2025 A 35,000 (3) (3) Common Stock 35,000 $0 35,000 D
    Explanation of Responses:
    1. The stock options have a 10-year term and vest 25% at one-year and monthly thereafter for 36 months, subject to the Reporting Person's continued service through each applicable vesting date.
    2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vivani common stock.
    3. The performance based RSUs shall vest in three stages: one-third when the stock price closes at or above $3.15 for three consecutive days, another one-third one year after this date when the market condition is first achieved, and the final one-third one year after this second vesting date when the market condition is achieved, subject to the Reporting Person's continued service through each applicable vesting date. If the RSUs fail to close at or above $3.15 for three consecutive trading dates within a four year term from the date of the grant, the RSUs shall expire.
    /s/ Brigid Makes as Attorney-in-fact 05/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VANI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VANI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VANI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Vivani Medical Inc.

      10-Q - Vivani Medical, Inc. (0001266806) (Filer)

      5/13/25 4:47:30 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      5/13/25 4:41:51 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFR14A filed by Vivani Medical Inc.

      DEFR14A - Vivani Medical, Inc. (0001266806) (Filer)

      5/6/25 4:11:17 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

      All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025 Announced new $3M equity financing together with the previously reported $8.25M equity financing secures financial position into mid-2026 Promising pre-clinical data released for NPM-139 (semaglutide implant) for chronic weight management in obese and overweight patients Company plans to spin off Cortigent, Inc., a division that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAME

      5/13/25 4:30:00 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical to Present at the American Association of Pharmaceutical Scientists' "Beyond GLP1s: Where the Science will Take Business Next" Virtual Workshop

      ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (the "Company" or "Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists' (AAPS) "Beyond GLP1s: Where the Science will Take Business Next" Virtual Workshop, taking place from May 13-14, 2025. Presentation details are as follows: Presentation: Addressing Patient Adherence: Advances in Drug DeliveryDate: Wednesday, May 14, 2025Time: 11:15 am, Eastern Time Dr. Mendelsohn will discuss Vivani's miniat

      5/7/25 8:30:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company

      Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D. to discuss the Company's LIBERATE-1 clinical trial from which topline data is anticipated in mid-year 2025 ALAMEDA, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced its participation in a virtual fireside chat hosted by Yi Chen, Ph.D., CFA, Managing Director of Equity Research at H.C. Wainwright & Company. As part of t

      4/16/25 8:30:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VANI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Director Williams Gregg bought $12,867 worth of shares (12,740 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      5/16/25 8:11:15 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Williams Gregg bought $1,124 worth of shares (1,113 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      4/28/25 7:59:38 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Williams Gregg bought $1,830 worth of shares (1,812 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      4/23/25 8:41:13 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)

      SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

      5/1/23 8:42:07 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by Vivani Medical Inc.

      SC 13D - Vivani Medical, Inc. (0001266806) (Subject)

      4/25/23 5:28:48 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Williams Gregg bought $12,867 worth of shares (12,740 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      5/16/25 8:11:15 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Business Officer Dwyer Donald

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      5/14/25 8:38:41 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Makes Brigid

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      5/14/25 8:31:54 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care